Insulet (PODD) is trading 5.1% down at $146.02 in pre-market following a voluntary correction and recall of certain lots of its Omnipod insulin delivery system.
- The company estimates a potential $50 million financial impact stemming from the recall, a figure that has rattled investor confidence despite management's reassurances.
- Shares are extending a sharp slide from yesterday’s after-hours session as the market reacts to the unexpected disclosure regarding the Omnipod device.